New anticoagulants: Moving on from scientific results to clinical implementation

References

• Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:160–98.
   PubMed Web of Science ®Google Scholar
• Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, . Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):381–453S.
   PubMedGoogle Scholar
• Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2004;140:175–83.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009;48:1–22.
   PubMed Web of Science ®Google Scholar
• Weitz JI. New oral anticoagulants in development. Thromb Haemost. 2010;103:62–70.
   PubMed Web of Science ®Google Scholar
• Ryn van J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, . Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–27.
   Google Scholar
• Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007;98:155–62.
   PubMed Web of Science ®Google Scholar
• Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost. 2007;98:333–8.
   PubMed Web of Science ®Google Scholar
• Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, . Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45:555–63.
   PubMed Web of Science ®Google Scholar
• Stangier J, Stahle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008; 48(12):1411–9.
   Google Scholar
• Troconiz IF, Tillmann C, Liesenfeld KH, Schafer HG, Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol. 2007;47(3):371–82.
   Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386–99.
   PubMed Web of Science ®Google Scholar
• Pezborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, . In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3:514–21.
   Google Scholar
• Pradaxa (dabigatran etexilate). Summary of product characteristics. Boehringer Ingelheim International GmbH. Available at: http://www.medicines.org.uk/emc/medicine/20760/SPC/ (accessed 2011).
   Google Scholar
• Connoly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Varrone J, Wang S, . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
   PubMed Web of Science ®Google Scholar
• Weinz C, Buetehorn U, Daehler HP, Kohlsdorfer C, Pleiss U, Sandmann S, . Pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—in rats and dogs. Xenobiotica. 2005;35:891–910.
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873–80.
   PubMed Web of Science ®Google Scholar
• Xarelto. Summary of product characteristics. Available at: http://www.xarelto.com/html/downloads/Xarelto_Summary_of_Product_Characteristics_May2009.pdf (accessed 2009).
   Google Scholar
• Halibi A, Maatouk H, Klause N, Lufft V, Kubitza D, Zuehlsdor M, . Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939)—an oral, direct, factor Xa inhibitor. Blood. 2006;108:Abstract 913. 2006.
   Google Scholar
• Gensch C, Hoppe U, Bohm M, Laufs U. Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010. Clin Res Cardiol. 2011;100:1–9.
   Web of Science ®Google Scholar
• Halibi A, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Maatouk H. Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban—an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2007;5(suppl 2):Abstract P-M-635. 2007.
   Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47:218–26.
   PubMed Web of Science ®Google Scholar
• FDA. Briefing information for the March 19, 2009 Cardiovascular and Renal Drugs Advisory Committee. Rivaroxaban: Advisory Committee Briefing Book. 2009.
   Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46:549–58.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, . A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3:103–11.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, . Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178–85.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, . Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949–56.
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, . Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1–9.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52.
   PubMed Web of Science ®Google Scholar
• Oldgren J, Budaj A, Granger CB, Harper R, Khder Y, Werf Fvd, . Randomised dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular compications also receiving aspirin and clopidogrel: RE-DEEM. Poster presented at: American Heart Association Scientific Sessions; 14–18 Nov 2009; Orlando (FL). 209.
   Google Scholar
• Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM. Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs. 2008;17:925–37.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, . Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765–75.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, . Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31–9.
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, Liberman JR, Rosencher N, Bandel TJ, . Rivaroxaban versus enoxaparin for thromboprohylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776–86.
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673–80.
   PubMed Web of Science ®Google Scholar
• Cao YB, Zhang JD, Shen H, Jiang YY. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2010;66:1099–108.
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, . Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363: 2499–510.
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, . Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009; 374:29–38.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121:1523–32.
   PubMed Web of Science ®Google Scholar
• Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Buller HR, Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood. 2008;111:4471–6.
   PubMed Web of Science ®Google Scholar
• Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. For. J Thromb Haemost. 2010;8: 621–6.
   PubMed Web of Science ®Google Scholar
• Bounameaux H, Reber G. New oral antithrombotics: a need for laboratory monitoring. Against. J Thromb Haemost. 2010;8:627–30.
   PubMed Web of Science ®Google Scholar
• Boneu B, de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost. 2001;27:519–22.
   Web of Science ®Google Scholar
• Walenga JM, Hoppensteadt DA. Monitoring the new antithrombotic drugs. Semin Thromb Hemost. 2004;30:683–95.
   PubMedGoogle Scholar
• Graff J, von Hentig N, Misselwitz F, Kubitza D, Becka M, Breddin HK, . Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol. 2007;47:1398–407.
   PubMed Web of Science ®Google Scholar
• Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau, Depasse F, . Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103:815–25.
   PubMed Web of Science ®Google Scholar
• Liesenfeld KH, Schafer HG, Troconiz IF, Tillmann C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006;62:527–37.
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292–303.
   PubMed Web of Science ®Google Scholar
• Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost. 2007;98:234–42.
   PubMed Web of Science ®Google Scholar
• Stangier J, Wetzel K, Wienen W, van RJ, Rathgen K. Measurement of the pharmacodynamic effect of dabigatran etexilate: thrombin clotting time. J Thromb Haemost. 2009;PP-TH-134.
   Google Scholar
• Mitchell LG, Dietrich K, Stang L, Etchers W, Qayyum S. Comparison of hemoclot to standard coagulation assays for monitoring the direct thrombin inhibitor (dabigatran) in pediatric patients: an in vitro study. J Thromb Haemost. 2009;PP-WE-448.
   Google Scholar
• Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost. 2010;104:1078–9.
   PubMed Web of Science ®Google Scholar
• Castellone DD, Peerschke EEIB. A chromogenic method for quantitation of direct thrombin inhibitors: a case study. J Thromb Haemost. 2007;5(Suppl 2):P-S-127.
   Google Scholar
• Bates SM, Weitz JI. Coagulation assays. Circulation. 2005;112:e53–e60.
   PubMed Web of Science ®Google Scholar
• Crowther MA, Warkentin TE. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost. 2009;7:107–10.
   PubMed Web of Science ®Google Scholar
• Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622–31.
   PubMed Web of Science ®Google Scholar
• Ryn van J, Dörr B, Kaspereit F, Krege W, Zeitler S, Pragst I. Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits (presented at the 21st International Congress on Thrombosis). Pathophysiol Haemost Thromb. 2010;37:A94-P486.
   Google Scholar
• Ryn van J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate (presented at the 13th Congress of the European Hematology Association). Haematologica. 2008;93:148–0370.
   Google Scholar
• Pezborn E, Trabandt A, Selbach K, Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats (presented at the 21st International Congress on Thrombosis). Pathophysiol Haemost Thromb. 2010; 37:A10-OC251.
   Google Scholar
• Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, . Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106:2550–4.
   PubMed Web of Science ®Google Scholar
• Pezborn E, Harwardt M. Recombinant factor VIIa partially reverses the effects of the factor Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro. J Thromb Haemost. 2007;5(suppl 2):P-W-640.
   Google Scholar
• Gruber A, Marzec M, Buetehorn U, Hanson SR, Pezborn E. Recombinant factor VIIa reverses the effects of a high dose of rivaroxaban in baboons. Pathophysiol Haemost Thromb. 2008;36(suppl 1):157–200 P 059.
   Google Scholar
• Ryn van J, Neubauer M, Flieg R, Krause B, Storr M, Hauel N, . Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system (presented at the 21st International Congress on Thrombosis). Pathophysiol Haemost Thromb. 2010; 37(suppl 1):P485.
   Google Scholar